Hoth Therapeutics reported that all evaluable patients in the open‑label pharmacokinetic cohort of the CLEER‑001 trial achieved a 100 % clinical response, with a ~50 % reduction in investigator‑assessed disease severity by week 6. This milestone confirms the therapy’s ability to mitigate the skin toxicities that often limit the use of epidermal growth factor receptor (EGFR) inhibitors.
Secondary endpoints also showed meaningful benefit. The trial recorded a ~34 % improvement in CTCAE‑graded oncology toxicity and a ~37 % reduction in patient‑reported pruritus. These results demonstrate that HT‑001 not only reduces the severity of skin lesions but also improves overall tolerability and quality of life for patients on EGFR‑targeted therapy.
The company’s CEO, Robb Knie, described the data as a “meaningful milestone” for HT‑001, underscoring the potential for the drug to become a standard supportive‑care product that could increase adherence to life‑saving cancer treatments. The findings also support the next phase of the program, a blinded, placebo‑controlled study that will further evaluate efficacy and safety.
Hoth remains a clinical‑stage biopharmaceutical with no product revenue and ongoing net losses. The interim data therefore represent a critical de‑risking event that could enhance the company’s ability to secure additional capital and attract strategic partners. Analysts have upgraded the company to a “Strong Buy” consensus, reflecting confidence in the therapeutic’s potential and the company’s execution.
Investors reacted positively to the announcement, reflecting confidence in the drug’s clinical promise and the company’s pipeline. The trial results also highlight Hoth’s focus on unmet needs in oncology supportive care, positioning it as a potential leader in this niche market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.